From: Role of aspirin discontinuation in recurrence of ischemic cerebrovascular stroke
Cases (n = 104) | Control (n = 104) | Test of sig. | p | |
---|---|---|---|---|
Aspirin Discontinuation | 53 (51.0%) | 30 (28.8%) | χ2 = 9.100* | 0.003* |
Cause of discontinuation | ||||
Switch to other antiplatelet | 9 (8.7%) | 5 (4.8%) | χ2 = 0.006 | 0.997 |
Non compliance | 32 (30.8%) | 18 (17.3%) | ||
Side effects | 12 (11.5%) | 7 (6.7%) | ||
Over the counter use | 0 (0%) | 0 (0%) | ||
Time of discontinuation (days) | ||||
0–7 | 0 (0%) | 6 (5.8%) | χ2 = 16.249* | < 0.001* |
8–30 | 25 (24%) | 18 (17.3%) | ||
31–180 | 13 (12.5%) | 4 (3.8%) | ||
> 181 | 15 (14.4%) | 2 (1.9%) | ||
Other drug discontinuation | ||||
No | 77 (74%) | 66 (63.5%) | χ2 = 3.156 | 0.237 |
Statins | 25 (24%) | 33 (31.7%) | ||
Antihypertensives | 2 (1.9%) | 5 (4.8%) | ||
History of NSAID use | 2 (1.9%) | 13 (12.5%) | χ2 = 8.694* | 0.003* |